体外生产红细胞:进展与挑战  

In Vitro Production of Red Blood Cells:Progress and Challenge

作　　者：王辉 张进进[2] 陈立力 邢颜超 WANG Hui;ZHANG Jinjin;CHEN Lili;XING Yanchao(School of Postgraduates,Xinjiang Medical University,Urumqi 830054,China;Department of Transfusion Medicine,General Hospital of Xinjiang Military Command,Urumqi 830000,China)

机构地区：[1]新疆医科大学研究生院,乌鲁木齐830054 [2]新疆军区总医院输血医学科,乌鲁木齐830000

出　　处：《协和医学杂志》2024年第1期166-171,共6页Medical Journal of Peking Union Medical College Hospital

基　　金：新疆维吾尔自治区自然科学基金面上项目(2022D01C342)。

摘　　要：目前临床用血供不应求,尽管自体输血等血液保护技术可部分缓解此类情况,但红细胞作为主要的血液成分需求量巨大,而体外生产安全的红细胞则可解决这一难题。目前研究显示,可从胚胎干细胞、人诱导多能干细胞、脐带血、外周血和永生化红系祖细胞系几种来源分化出成熟红细胞。本文就体外生产红细胞的来源及应用进行综述,并分析目前所面临的挑战,以期为输血治疗提供新思路。Although blood protection technologies such as autologous blood transfusion can alleviate to some extent the short supply of clinical blood,red blood cells are still in great demand as the main blood component.This problem can be solved by the safe production of red blood cells in vitro.At present,mature erythrocytes can be differentiated from embryonic stem cells,human induced pluripotent stem cells,umbilical cord blood,peripheral blood,and immortalized erythroid progenitor cell lines.This article reviews the sources and applications of red blood cells produced in vitro,and analyzes the current challenges,in order to provide new insights for blood transfusion therapy.

关 键 词：体外生产红细胞 胚胎干细胞 永生化红系祖细胞系 输血 

分 类 号：R457.1[医药卫生—治疗学]